Physician profile
Andrew Flum
NPI 1861712671
$6,175.75
in general payments reported to CMS, 2019-2025
46 companies · $2,799 in 2025
The $2,799 reported for 2025 was more than what 86% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2020: $102 · 2021: $488 · 2022: $683 · 2023: $959 · 2024: $873 · 2025: $2,799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,789 · Travel and Lodging: $1,671 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,789.40 |
| Travel and Lodging | $1,671.18 |
| Education | $170.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Telix Pharmaceuticals | $2,163.64 | 2025 | Illuccix |
| Astellas Pharma US INC | $520.17 | 2019-2024 | Myrbetriq, Veozah, Xtandi |
| Dendreon Pharmaceuticals LLC | $356.45 | 2021-2024 | Provenge |
| Janssen Biotech, INC. | $300.91 | 2021-2025 | Erleada, Akeega, Balversa |
| Abbvie INC. | $293.69 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $287.02 | 2021-2025 | |
| Progenics Pharmaceuticals, INC. | $205.92 | 2021-2025 | Pylarify |
| Novartis Pharmaceuticals Corporation | $204.58 | 2023-2025 | |
| Urogen Pharma, INC. | $169.16 | 2021-2025 | |
| Blue Earth Diagnostics | $126.68 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $124.90 | 2022-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Procept Biorobotics Corporation | $105.67 | 2022-2025 | Aquabeam System |
| Sumitomo Pharma America, INC. | $86.84 | 2023-2025 | Orgovyx, Gemtesa |
| Ferring Pharmaceuticals INC. | $80.79 | 2019-2025 | Adstiladrin |
| Tolmar, INC. | $78.37 | 2023-2025 | Eligard |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rochester Medical Corporation | $78.23 | 2022 | |
| Boston Scientific Corporation | $77.56 | 2021-2025 | Spaceoar System, Spaceoar Vue System - 10ml |
| Coloplast Corp | $70.91 | 2021-2024 | |
| Amgen INC. | $70.26 | 2020-2023 | Prolia |
| Myovant Sciences INC. | $65.94 | 2021-2022 | |
| C. R. Bard, INC. & Subsidiaries | $53.85 | 2023 | Bard Urinary Drainage Bag |
| Myriad Genetic Laboratories, INC. | $48.91 | 2021-2025 | Prolaris |
| Becton, Dickinson and Company | $48.61 | 2023 | Bard Urinary Drainage Bag |
| Endo Pharmaceuticals INC. | $45.82 | 2019-2022 | |
| Caris Mpi, INC. | $44.84 | 2025 | Mi Cancer Seek |
| Astrazeneca Pharmaceuticals LP | $36.92 | 2023-2025 | Lynparza |
| Pfizer INC. | $36.00 | 2019-2020 | |
| Olympus America INC. | $31.98 | 2022-2025 | Itind System |
| Angiodynamics, INC. | $28.68 | 2023 | Nanoknife |
| Aytu Biopharma, INC. | $27.71 | 2019 | |
| Baxter Healthcare | $26.95 | 2024 | Perclot |
| Axonics, INC. | $26.89 | 2024 | Bulkamid |
| Urovant Sciences INC | $26.54 | 2021-2022 | |
| Ambu INC. | $25.52 | 2021 | |
| Convatec INC. | $23.56 | 2021 | |
| Travere Therapeutics, INC. | $20.67 | 2021 | |
| Immunitybio, INC. | $20.02 | 2025 | |
| Kerecis Limited | $17.72 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Azurity Pharmaceuticals, INC. | $17.27 | 2025 | Azmiro |
| Biotissue Holdings INC. | $16.76 | 2023 | |
| 180 Medical, INC. | $14.78 | 2019 | |
| Verity Pharmaceuticals INC. | $14.57 | 2025 | Trelstar |
| Cycle Pharmaceuticals INC | $14.38 | 2025 | Venxxiva |
| Antares Pharma, INC. | $13.86 | 2019 | |
| Accord Healthcare, INC. | $13.64 | 2023 | |
| Clarus Therapeutics INC. | $11.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Flum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.